COGT - Cogent Biosciences, Inc.
IEX Last Trade
7.77
0.045 0.579%
Share volume: 20,693
Last Updated: Fri 27 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$7.72
0.05
0.58%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
1.42%
1 Month
-17.85%
3 Months
-27.80%
6 Months
-6.75%
1 Year
34.07%
2 Year
-26.99%
Key data
Stock price
$7.77
DAY RANGE
$7.62 - $7.83
52 WEEK RANGE
$4.50 - $12.61
52 WEEK CHANGE
$33.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Andrew R. Robbins
Region: US
Website: cogentbio.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cogentbio.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.
Recent news